Tivic Health Names Interim CFO and Strategic Board Advisor

Tivic Health Systems Inc. has appointed Kimberly Bambach as Interim chief financial officer (CFO) and Christina Valauri as a strategic advisor to the Board of Directors. Bambach replaces Veronica Cai, who had served as CFO since April 2022. 
 
Bambach brings more than 30 years of financial leadership experience in both public and private companies across industries. Her background includes financial leadership in medical and retail markets, manufacturing, wholesale distribution, licensing, digital media, and broadcasting. Bambach most recently served as CFO of Jushi Holdings Inc., where she played a pivotal role in the company’s rapid growth driving over a dozen acquisitions in a complex regulatory environment. Since leaving Jushi, Bambach has continued as an advisor to the company while providing consulting services to several private companies. Before Jushi, Bambach held executive leadership and finance positions in both public and private equity companies. She earned a bachelor of arts degree from SUNY Brockport and an MBA from Pace University.
 
“I am pleased to have such an experienced financial leader join our leadership team,” Tivic Health CEO Jennifer Ernst said. “As we prepare Tivic for the future in a rapidly evolving health tech market, I am confident that Kimberly’s strong leadership and expertise in financial and operational improvements will have an immediate positive impact on our company.”
 
Valauri will serve as a strategic advisor to Tivic’s Board of Directors. She brings a 30-year proven track record as a senior healthcare analyst, including leadership roles as U.S. and global head of Equity Research and managing director at Cantor Fitzgerald. She is the founding partner and CEO of Sagestone Advisory LLC and a partner of NextGen Venture Partners, an early-stage venture capital firm with a network of 1,600 proven entrepreneurs and accomplished professionals. Her background in equity securities research has provided a deep base of experience in medtech, pharmaceutical, and biotech companies. She has extensive experience identifying and analyzing the commercial potential of breakthrough innovations, as well as mentoring and advising the C-suite teams of private and public early-stage healthcare companies through product development, regulatory, go-to-market strategies, potential mergers and acquisitions, and IPOs. She has successfully developed and executed transformational business strategies to drive growth and enhance operating performance.
 
Valauri has previously held senior roles at U.S. and international firms including ING, Credit Lyonnais (acquired by Credit Agricole), Natixis, and was the global director of Research for Cantor Fitzgerald. She has been recognized by The Wall Street Journal’s “Best on The Street” All Star Analyst Survey and has received the Award for Excellence – Medical Education Public Affairs Association of American – Medical Colleges – New York University. She currently serves as a senior advisor with Hanover International Inc., Astia.org, and as a mentor and advisor at the Weill Cornell Medicine BioVenture eLab. Valauri earned a bachelor of arts degree in biology from Reed College and an MBA from Cornell University.
 
“The Board and I value the astute insight and understanding of emerging growth companies Christina is bringing to this board advisory role,” Ernst stated. “Christina is a seasoned financial steward and her expertise will be invaluable to our evaluation of transformational growth opportunities through internal development, strategic partnerships and M&A to drive value for our shareholders and customers.”
 
Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Its non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic’s first commercial product ClearUP is a U.S. Food and Drug Administration-approved, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors.